Bots, editor, reviewer, Administrators
13,951
edits
No edit summary |
No edit summary |
||
Line 40: | Line 40: | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2014-05-23T21:17:56Z", | ||
"briefDesignDescription" : "Benazepril/amlodipine vs. benazepril/HCTZ in HTN", | "briefDesignDescription" : "Benazepril/amlodipine vs. benazepril/HCTZ in HTN", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0806182", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0806182", | ||
"pageid" : 1448, | "pageid" : 1448, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0806182", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0806182", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident\n}}", | ||
"citation" : "Jamerson K, <i>et al</i>. \"Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients\". <i>The New England Journal of Medicine</i>. 2008. 359(23):2417-2428.", | "citation" : "Jamerson K, <i>et al</i>. \"Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients\". <i>The New England Journal of Medicine</i>. 2008. 359(23):2417-2428.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
Line 1,930: | Line 1,930: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2014-05- | "timestamp" : "2014-05-23T21:16:05Z", | ||
"briefDesignDescription" : "Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM", | "briefDesignDescription" : "Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0801317", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0801317", | ||
"pageid" : 1776, | "pageid" : 1776, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0801317", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0801317", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident \n}}", | ||
"citation" : "Yusuf S, <i>et al</i>. \"Telmisartan, ramipril, or both in patients at high risk for vascular events\". <i>The New England Journal of Medicine</i>. 2008. 358(15):1547-1559.", | "citation" : "Yusuf S, <i>et al</i>. \"Telmisartan, ramipril, or both in patients at high risk for vascular events\". <i>The New England Journal of Medicine</i>. 2008. 358(15):1547-1559.", | ||
"subspecialties" : "Cardiology;Nephrology;Endocrinology", | "subspecialties" : "Cardiology;Nephrology;Endocrinology", |